<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04822077</url>
  </required_header>
  <id_info>
    <org_study_id>PROTHYM 2.2</org_study_id>
    <nct_id>NCT04822077</nct_id>
  </id_info>
  <brief_title>Study on Proton Radiotherapy of Thymic Malignancies</brief_title>
  <acronym>PROTHYM</acronym>
  <official_title>PROTHYM - Phase II Non-randomized Study on Proton Radiotherapy Of Thymic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ass. Prof. Jan Nyman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swedish Lung Cancer Study Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicentre non-randomized phase II study of proton beam radiotherapy in patients&#xD;
      with thymic epithelial tumours (i.e. thymoma and thymic carcinoma) in the post-operative&#xD;
      setting or in inoperable patients with localized disease.&#xD;
&#xD;
      Patients not willing or for any reason unsuitable to undergo proton treatment will be asked&#xD;
      to participate in a follow-up assessment after the regular photon treatment in the same&#xD;
      manner as the included patients.&#xD;
&#xD;
      Primary endpoints are:Toxicity (e.g. cardiac and pulmonary toxicity) and Local control at 5&#xD;
      year Secondary endpoints: PFS, Overall survival, Quality of life, measured by EORTC QLQ 30 +&#xD;
      LC 13 and relapse pattern&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All doses are recorded in Gy(RBE).&#xD;
&#xD;
      After having checked all eligibility criteria patients will receive:&#xD;
&#xD;
        -  Patients with radical surgery and unfavourable histology (B2, B3, C) and/or Masaoka-Koga&#xD;
           stage III, IVa: 2 Gy(RBE), once daily, five days a week to a total dose of 50 Gy(RBE).&#xD;
&#xD;
        -  Patients with non-radical surgery (R1 resection) regardless of stage and histology: 2.3&#xD;
           Gy(RBE), once daily, 5 days a week to a total dose of 57.5 Gy(RBE)&#xD;
&#xD;
        -  Inoperable patients regardless of stage and histology and patients with R2 non-radical&#xD;
           resection: 2.5 Gy (RBE), once daily, 5 days a week to a total dose of 62.5 Gy(RBE)&#xD;
&#xD;
        -  Patients not willing to participate in study will receive photon therapy according to&#xD;
           local practice (≥45 Gy)&#xD;
&#xD;
      Induction or adjuvant chemotherapy may be used according to local practice. Concomitant&#xD;
      chemotherapy is not allowed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 18, 2018</start_date>
  <completion_date type="Anticipated">April 1, 2029</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Phase II study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiotoxicity and pulmonary toxicity of therapy</measure>
    <time_frame>At 60 months from treatment</time_frame>
    <description>Proportion of patients with cardiac and pulmonary toxicity measured by CTCAE 4.0 &gt; Grade 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Local tumor control</measure>
    <time_frame>At 60 months from treatment</time_frame>
    <description>Freedom from tumor progression (CR,PR or SD) mesured by CT-scan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire EORTC QLQ 30 (European Organisation for Research and Treatment of Cancer)</measure>
    <time_frame>At 60 months from treatment</time_frame>
    <description>Scale from 1-100 for 30 items, higher score indicates a better situation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire LC13 (Lung cancer specific module of EORTC)</measure>
    <time_frame>At 60 months from treatment</time_frame>
    <description>Scale from 1-100 for 13 items and higher score indicates worse symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>From treatment and for 5 years</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cardiotoxicity</condition>
  <condition>Pulmonary Toxicity</condition>
  <condition>Thymus Neoplasms</condition>
  <arm_group>
    <arm_group_label>Proton radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Proton radiotherapy with RBE doses:&#xD;
Patients with radical surgery and unfavourable histology (B2, B3, C) and/or Masaoka-Koga stage III, IVa: 2 Gy(RBE), once daily, five days a week to a total dose of 50 Gy(RBE).&#xD;
Patients with non-radical surgery (R1 resection) regardless of stage and histology: 2.3 Gy(RBE), once daily, 5 days a week to a total dose of 57.5 Gy(RBE)&#xD;
Inoperable patients regardless of stage and histology and patients with R2 non-radical resection: 2.5 Gy (RBE), once daily, 5 days a week to a total dose of 62.5 Gy(RBE)</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Proton radiation</intervention_name>
    <description>Patients with radical surgery and unfavourable histology (B2, B3, C) and/or Masaoka-Koga stage III, IVa: 2 Gy(RBE), once daily, five days a week to a total dose of 50 Gy(RBE).&#xD;
Patients with non-radical surgery (R1 resection) regardless of stage and histology: 2.3 Gy(RBE), once daily, 5 days a week to a total dose of 57.5 Gy(RBE)&#xD;
Inoperable patients regardless of stage and histology and patients with R2 non-radical resection: 2.5 Gy (RBE), once daily, 5 days a week to a total dose of 62.5 Gy(RBE)</description>
    <arm_group_label>Proton radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological or cytological diagnosis of thymoma or thymic carcinoma.&#xD;
&#xD;
          -  With radical surgery: stage III and IVa and selected stage II with type B2, B3 and&#xD;
             thymic carcinoma according to local routine. With non-radical surgery (R1 or R2) or&#xD;
             inoperable patient/ patient refusing surgery: stage I - IVa, any histology&#xD;
&#xD;
          -  PS WHO 0 - 2.&#xD;
&#xD;
          -  FEV1 &gt; 1L or &gt;40 % of predicted and CO diffusion capacity &gt; 40% of predicted&#xD;
             (postoperative measures)&#xD;
&#xD;
          -  Age &gt;18 years, no upper age limit.&#xD;
&#xD;
          -  Written informed consent from patients.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Masaoka-Koga stage IVb (distant metastases).&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Serious concomitant systemic disorder incompatible with the study.&#xD;
&#xD;
          -  Tumour motion &gt; 0.5 cm on two repeated 4DCT&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hillevi Rylander, MD</last_name>
    <role>Study Director</role>
    <affiliation>Head of Skandion Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jan Nyman, Ass.prof.</last_name>
    <phone>+46313421000</phone>
    <phone_ext>27927</phone_ext>
    <email>jan.nyman@oncology.gu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andreas Hallqvist, MD, PhD</last_name>
    <phone>+46739845114</phone>
    <email>andreas.hallqvist@vgregion.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Oncology, Norrlands Universitetssjukhus</name>
      <address>
        <city>Umeå</city>
        <state>Norrland</state>
        <zip>901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikael Johansson, MD PhD</last_name>
      <phone>0046703711414</phone>
      <email>mikael.johansson@onkologi.umu.se</email>
    </contact>
    <contact_backup>
      <last_name>Per Bergström, MD PhD</last_name>
      <email>per.bergstrom@vll.se</email>
    </contact_backup>
    <investigator>
      <last_name>Mikael Johansson, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Per Bergström, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <state>Stockholm County</state>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Signe Friesland, MD PhD</last_name>
      <email>signe.friesland@sll.se</email>
    </contact>
    <contact_backup>
      <last_name>Michael Gubanski, MD PhD</last_name>
      <email>michael.gubanski@sll.se</email>
    </contact_backup>
    <investigator>
      <last_name>Signe Friesland, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Gubanski, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <state>Västra Götaland</state>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Nyman, Ass prof</last_name>
      <phone>0046313427927</phone>
      <email>jan.nyman@oncology.gu.se</email>
    </contact>
    <contact_backup>
      <last_name>Andreas Hallqvist, MD, PhD</last_name>
      <phone>+46739845114</phone>
      <email>andreas.hallqvist@vgregion.se</email>
    </contact_backup>
    <investigator>
      <last_name>Andreas Hallqvist, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Annica Ravn-Fischer, MD phD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hillevi Rylander, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Bäck, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erik Lundin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jens Engleson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jan Nyman, Ass prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <results_reference>
    <citation>Chang JY, Li H, Zhu XR, Liao Z, Zhao L, Liu A, Li Y, Sahoo N, Poenisch F, Gomez DR, Wu R, Gillin M, Zhang X. Clinical implementation of intensity modulated proton therapy for thoracic malignancies. Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):809-18. doi: 10.1016/j.ijrobp.2014.07.045. Epub 2014 Sep 24.</citation>
    <PMID>25260491</PMID>
  </results_reference>
  <results_reference>
    <citation>Gomez D, Komaki R. Technical advances of radiation therapy for thymic malignancies. J Thorac Oncol. 2010 Oct;5(10 Suppl 4):S336-43. doi: 10.1097/JTO.0b013e3181f20ea2. Review.</citation>
    <PMID>20859129</PMID>
  </results_reference>
  <results_reference>
    <citation>Vogel J, Berman AT, Lin L, Pechet TT, Levin WP, Gabriel P, Khella SL, Singhal S, Kucharczuk JK, Simone CB 2nd. Prospective study of proton beam radiation therapy for adjuvant and definitive treatment of thymoma and thymic carcinoma: Early response and toxicity assessment. Radiother Oncol. 2016 Mar;118(3):504-9. doi: 10.1016/j.radonc.2016.02.003. Epub 2016 Feb 16.</citation>
    <PMID>26895711</PMID>
  </results_reference>
  <results_reference>
    <citation>Björk-Eriksson T, Bjelkengren G, Glimelius B. The potentials of proton beam radiation therapy in malignant lymphoma, thymoma and sarcoma. Acta Oncol. 2005;44(8):913-7. Review.</citation>
    <PMID>16332601</PMID>
  </results_reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 11, 2021</study_first_submitted>
  <study_first_submitted_qc>March 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2021</study_first_posted>
  <last_update_submitted>March 25, 2021</last_update_submitted>
  <last_update_submitted_qc>March 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Swedish Lung Cancer Study Group</investigator_affiliation>
    <investigator_full_name>Ass. Prof. Jan Nyman</investigator_full_name>
    <investigator_title>Head of Swedish Lung Cancer Study Group, Ass. Prof.</investigator_title>
  </responsible_party>
  <keyword>Thymoma</keyword>
  <keyword>Thymic carcinoma</keyword>
  <keyword>Proton radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thymus Neoplasms</mesh_term>
    <mesh_term>Thymoma</mesh_term>
    <mesh_term>Cardiotoxicity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The aim is that the study will be published in international journals. A separate publication will include result of the cardiological data The Vancouver declaration (Br Med J:296, 401-405, 1988) should be followed in all publications based on this study.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 21, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT04822077/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

